Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun;12(3):2107-2112.
doi: 10.1002/ehf2.15220. Epub 2025 Jan 26.

Temporal profiling of M-TEER-related complications

Jafer Haschemi  1 , Hanna Schrameck  1 , Jean Marc Haurand  1 , Daniel Oehler  1 , Maximilian Spieker  1 , Fabian Voss  1 , Malte Kelm  1   2 , Amin Polzin  1 , Patrick Horn  1
Affiliations

Temporal profiling of M-TEER-related complications

Jafer Haschemi et al. ESC Heart Fail. 2025 Jun.

Abstract

Aims: Transcatheter edge-to-edge repair of the mitral valve (M-TEER) is known for its low complication rates. However, the optimal level and duration of post-procedural care remain unclear. This study aimed to identify the specific timeframe of post-procedural complications following M-TEER.

Methods and results: We conducted a retrospective analysis of 865 patients who underwent M-TEER at the University Hospital Düsseldorf between August 2010 and August 2023. Our analysis focused on a comprehensive examination of all acute post-procedural complications (1-100 h), considering the time point of occurrence or diagnosis. The complication analysed included cardiogenic shock, pericardial tamponade, stroke, cardiac arrhythmias, bleeding, acute kidney injury, myocardial infarction, peripheral vascular ischaemia and in-hospital mortality.

Results: The median age was 80 (74, 84) years, and the EuroScore II was high (6.5 [4.0, 12.0] %). Functional mitral regurgitation (MR) was more common than degenerative or mixed MR (69% vs. 20%. respectively; 11%). Technical success rate was 97.2%. Overall, acute post-procedural complications occurred in 87 patients (10.1%). Most complications (75.9%) occurred within the first 4 h post-procedure. 12.6% of the complications occurred during the period between 4 and 24 h post-procedure, and 11.5% of the complications happened between 24 and 100 h post-procedure. Life-threatening complications were observed only within the first 4 h post-procedure.

Conclusions: The majority of post-procedural complications after M-TEER occur within the first 4 h, with pericardial tamponade and major bleeding occurring only during this period. These findings provide valuable insight for physicians in determining the optimal surveillance and monitoring duration after M-TEER within clinical settings.

Keywords: Events; MitraClip; Mitral regurgitation; Pascal; Safety.

PubMed Disclaimer

Conflict of interest statement

P.H. has received travel support and educational grant from Abbott Medical GmbH and Edwards Lifesciences and an unrestricted research grant from Edwards Lifesciences.

Figures

Figure 1
Figure 1
Occurrence of acute M‐TEER‐related complications over time. Occurrence of post‐procedural complication (A) in the first 24 h and (B) between 24 and 100 h after the end of M‐TEER procedure. Post‐M‐TEER time zones are classified according to the timing and severity of complications following the procedure: red zone (0–4 h); yellow zone (4–24 h) and green zone (24–100 h). M‐TEER, transcatheter edge‐to‐edge repair of the mitral valve; RRT, renal replacement therapy.
See this image and copyright information in PMC

References

    1. Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, et al. 2021 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J 2021;43:561‐632. doi:10.1093/eurheartj/ehab395 - DOI - PubMed
    1. Otto C, Nishimura R, Bonow R, Carabello B, Erwin J III, Gentile F, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol 2021;77:450‐500. doi:10.1016/j.jacc.2020.11.035 - DOI - PubMed
    1. Rudolph V, von Bardeleben RS, Friede T, Hausleiter J, Ince H, Mathes T, et al. Contemporary safety outcomes of mitral edge‐to‐edge repair in Germany. JACC Cardiovasc Interv 2023;16:2939‐2941. doi:10.1016/j.jcin.2023.09.013 - DOI - PubMed
    1. Bedogni F, Testa L, Rubbio AP, Bianchi G, Grasso C, Scandura S, et al. Real‐world safety and efficacy of Transcatheter mitral valve repair with MitraClip: thirty‐day results from the Italian Society of Interventional Cardiology (GIse) registry of Transcatheter Treatment of Mitral Valve RegurgitaTiOn (GIOTTO). Cardiovasc Revasc Med 2020;21:1057‐1062. doi:10.1016/j.carrev.2020.01.002 - DOI - PubMed
    1. Mack M, Carroll JD, Thourani V, Vemulapalli S, Squiers J, Manandhar P, et al. Transcatheter mitral valve therapy in the United States: a report from the STS‐ACC TVT registry. J Am Coll Cardiol 2021;78:2326‐2353. doi:10.1016/j.jacc.2021.07.058 - DOI - PubMed

LinkOut - more resources